Fang Sun
Neuromuscular Medicine · Pittsburgh, PANPI 1831585322
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,425 of the $2,193 with a category attached, or 65.0%. Argenx US, Inc. accounts for 71.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $1,425 and has fallen 84.5% since, to $221 in 2025.
Across 9 payments — averaging $243.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$2K
- UCB, Inc.$270
- Sanofi$115
- Sarepta Therapeutics, Inc.$95
- Johnson & Johnson$85
- Bristol Myers Squibb$50
- plus $10 from 1 others
Across 13 payments — averaging $2841.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$26K
- Argenx US, Inc.$9K
- Novartis$2K
What the payments were for
- Consulting fees$1,42565%
- Food & beverage$68331%
- Education$854%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 2 | $1,568 |
| UCB, Inc. | 2 | $270 |
| Sanofi | 1 | $115 |
| Sarepta Therapeutics, Inc. | 1 | $95 |
| Johnson & Johnson | 1 | $85 |
| Bristol Myers Squibb | 1 | $50 |
| Kedrion Biopharma, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$143
How this compares
Too few neuromuscular medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 31 | $477,168 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $314,619 |
| Pyridostigmine Bromide | 238 | $11,508 |
| Mycophenolate Mofetil | 85 | $8,259 |
| Prednisone | 232 | $1,454 |
| Gabapentin | 70 | $603 |
| Omeprazole | 44 | $483 |
| Esomeprazole Magnesium | 11 | $98 |
| Pantoprazole Sodium | 14 | $69 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $58 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Pittsburgh
- Tawfiq Al LahhamPittsburgh$214
- Paul McIntoshPhiladelphia$49K
- Hristelina IlievaPhiladelphia$5K
- Sara DehbashiPhiladelphia$856
- Naaima MuftiEaston$629
- Gema Giler-SacotoPhiladelphia$527
- Jessica YiPhiladelphia$340
- Connie TangAllentown$261
- Rebecca HsuPhiladelphia$191
- Vanessa DwairiErie$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.